Abstract
The epidermal growth factor receptor (EGFR) has become an important molecular target in cancer therapy. Various small molecules and therapeutic antibodies targeting EGFR family members have been developed during recent years and are established in clinical oncology. However, increasing clinical application of EGFR tyrosine kinase inhibitors has resulted in the development of resistance to EGFR-targeting drugs due to the selection of EGFR-mutated variants. This phenomenon forced the search for novel EGFR inhibitors with activity towards EGFR-mutant tumors. This review describes recent achievements in natural products derived from medicinal plants as novel EGFR inhibitors.
Keywords: Cancer, drug resistance, epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitor, medicinal plant, natural product, head and neck squamous cell cancer, HNSCC, renal cancer, ovarian cancer, vinblastine, vincristine, paclitaxel, camptothecin, Cephalotaxus hainanensis, cephalotaxine, CET, ester homoharringtonine, Artemisia annua, Magnolia officinalis, small cell carcinoma, SCC, non-small cell carcinoma, small cell lung carcinoma, SCLC, cell lung carcinoma, NSCLC, Oral squamous cell carcinoma, OSCC, Magnoliae Cortex, CPT, Lithospermum erythrorhizon, Rabdosia rubescens, Lithospermum radix
Combinatorial Chemistry & High Throughput Screening
Title: Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Volume: 13 Issue: 10
Author(s): Serkan Sertel, Peter K. Plinkert and Thomas Efferth
Affiliation:
Keywords: Cancer, drug resistance, epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitor, medicinal plant, natural product, head and neck squamous cell cancer, HNSCC, renal cancer, ovarian cancer, vinblastine, vincristine, paclitaxel, camptothecin, Cephalotaxus hainanensis, cephalotaxine, CET, ester homoharringtonine, Artemisia annua, Magnolia officinalis, small cell carcinoma, SCC, non-small cell carcinoma, small cell lung carcinoma, SCLC, cell lung carcinoma, NSCLC, Oral squamous cell carcinoma, OSCC, Magnoliae Cortex, CPT, Lithospermum erythrorhizon, Rabdosia rubescens, Lithospermum radix
Abstract: The epidermal growth factor receptor (EGFR) has become an important molecular target in cancer therapy. Various small molecules and therapeutic antibodies targeting EGFR family members have been developed during recent years and are established in clinical oncology. However, increasing clinical application of EGFR tyrosine kinase inhibitors has resulted in the development of resistance to EGFR-targeting drugs due to the selection of EGFR-mutated variants. This phenomenon forced the search for novel EGFR inhibitors with activity towards EGFR-mutant tumors. This review describes recent achievements in natural products derived from medicinal plants as novel EGFR inhibitors.
Export Options
About this article
Cite this article as:
Sertel Serkan, K. Plinkert Peter and Efferth Thomas, Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor, Combinatorial Chemistry & High Throughput Screening 2010; 13 (10) . https://dx.doi.org/10.2174/138620710793360266
DOI https://dx.doi.org/10.2174/138620710793360266 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment
Current Alzheimer Research Radiolabeled Glucose Derivatives for Tumor Imaging Using SPECT and PET
Current Medicinal Chemistry Laminin-332-Integrin Interaction: A Target For Cancer Therapy?
Current Medicinal Chemistry Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO)
Current Radiopharmaceuticals Triazole as Potent Anti-cancer Agent- A Pharmacophoric Scaffold
Current Cancer Therapy Reviews Dual Induction of Mitochondrial Apoptosis and Senescence in Chronic Myelogenous Leukemia by Myrtucommulone A
Anti-Cancer Agents in Medicinal Chemistry Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Applications of Polymeric Nanocapsules in Field of Drug Delivery Systems
Current Drug Discovery Technologies Interaction of Prolyl Oligopeptidase with α-Synuclein
CNS & Neurological Disorders - Drug Targets Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Apoptosis is a Critical Cellular Event in Cancer Chemoprevention and Chemotherapy by Selenium Compounds
Current Cancer Drug Targets Glioblastoma Multiforme Formation and EMT: Role of FoxM1 Transcription Factor
Current Pharmaceutical Design CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry Stopping Cancer in its Tracks: Using Small Molecular Inhibitors to Target Glioblastoma Migrating Cells
Current Drug Discovery Technologies P53 Gene Therapy Sensitizes Resistant Breast Cancer Cells to Doxorubicin Chemotherapy
Drug Delivery Letters